Julie R. McMullen

Julie R. McMullen

Baker Heart and Diabetes Institute

Affiliated withBaker Heart and Diabetes InstituteLa Trobe UniversityMonash University

+1

Research Area

Biography

Professor Julie McMullen (PhD) heads the Cardiac Hypertrophy Laboratory at the Baker Heart and Diabetes Institute (VIC, AUSTRALIA) and is Head of the Discovery & Preclinical Domain at the Institute. Her research interests include physiological and pathological cardiac hypertrophy, heart failure, atrial fibrillation, gene therapy and cardiotoxicity. Prof McMullen is recognised internationally for research which defined the molecular distinction between physiological and pathological heart growth/cardiac hypertrophy in mouse models of health and disease. She discovered that a signalling pathway activated with exercise (PI3K pathway) was critical for physiological hypertrophy (e.g. athlete’s heart) but not pathological hypertrophy (e.g. setting of hypertension). She has published her research in leading journals including PNAS, Circulation, Circulation-Heart Failure, Nature Communications, Cell Reports, and Diabetes. She sits on the Editorial Board of Clinical Science and the American Journal of Physiology-Heart and Circulatory Physiology, and is a Fellow of the American Heart Association and International Society for Heart Research.

JoVE Journal Publications

ArticleTotal : 1
Year
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
Publication title

Cited by 1

2021

Other Publications

Article
Year
Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 17202264

2007
2007
PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.

Cell cycle (Georgetown, Tex.)| PubMed ID: 17404510

2007
Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease.

Clinical and experimental pharmacology & physiology| PubMed ID: 18290876

2008
2017
2017
2017
2017
2018
2018
2018
Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β-adrenoceptor overexpression.

American journal of physiology. Heart and circulatory physiology| PubMed ID: 29424570

2018
2018
2018
Improving the quality of preclinical research echocardiography: observations, training, and guidelines for measurement.

American journal of physiology. Heart and circulatory physiology| PubMed ID: 29677464

2018
2018
2018
2018
2018
2018
Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling.

American journal of physiology. Heart and circulatory physiology| PubMed ID: 30387702

2019
2019
Noncoding RNAs regulating cardiac muscle mass.

Journal of applied physiology (Bethesda, Md. : 1985)| PubMed ID: 30571279

2019
2019
2019
2019
Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.

American journal of physiology. Heart and circulatory physiology| PubMed ID: 32142359

2020
2020
2020
2021
2020
2021
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.

American journal of physiology. Heart and circulatory physiology| PubMed ID: 33577435

2021
2021
2021
Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art Review.

Journal of the American College of Cardiology| PubMed ID: 34082914

2021
2021
2021